Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Quest Diagnostics Incorporated
DGX
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $23.9B
$216.19
▲ +0.08%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$164.65 - $217.41
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive Laboratory Network
- Comprehensive Diagnostic Testing Portfolio
- Advanced Information Technology Infrastructure
- Strong Relationships with Healthcare Providers
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Increasing Healthcare Diagnostic Needs
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Strong
+9.1% over 3m
Quality
Stable
Excellent business quality
Dividend
Modest
1.51% yield
Smart-money signal
Who's buying DGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 20, 2026
APR 21, 2026
Reported EPS of $2.50 vs $2.37 consensus (+5.5% surprise). Revenue of $2.9B vs $2.8B expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+5.5%
Next: Apr 20, 2026
Revenue trend · last 8Q
—
—
+15%
+12%
+15%
+13%
+7%
+9%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.4B
$2.5B
$2.6B
$2.7B
$2.8B
$2.8B
$2.8B
$2.9B
Margins · last 8Q
Gross
32.5%
Operating
13.8%
Profit
8.7%
Wall Street consensus
8 analysts · 38% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
38%
Hold
63%
Sell
0%
Median Price Target
$225.00
▲ +4.1% vs $216.19
Latest: UBS · Apr 22, 2026
2 analysts covering